OXiGENE Regains NASDAQ Closing Bid Price Compliance
March 15, 2011 18:44 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 15, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Reports Full Year 2010 Financial Results
March 03, 2011 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Receives Listing Decision From NASDAQ
March 02, 2011 17:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Fourth Quarter and Fiscal 2010 Earnings Conference Call and Webcast
February 28, 2011 09:01 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE to Collaborate With NCI/CTEP, GOG on Phase 2 Study of ZYBRESTAT in Patients With Relapsed Ovarian Cancer
February 14, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Provides Update on Near-Term Corporate Events
February 10, 2011 07:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE to Present at BIO CEO and Investor Conference on February 14, 2011
February 04, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Enters Into Exchange Agreements With Warrant Holders
January 19, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Further Positive Safety and Efficacy Data From Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer
November 19, 2010 02:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Third Quarter 2010 Financial Results
November 04, 2010 11:24 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc., (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...